Seizure News and Research

Latest Seizure News and Research

Insight into beneficial epilepsy treatments for children with autism

Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.

3 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

FDA warns online retailers for illegal tobacco product marketing

The U.S. Food and Drug Administration today announced it issued 11 warning letters last week to online retailers for illegally marketing tobacco products with misleading or unsubstantiated claims or descriptors indicating that they can be used to reduce harm or the risk of tobacco-related disease.

26 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

Study provides insight into effective treatments for autism spectrum disorder, seizures

Roughly 25-35% of individuals with autism eventually develop seizures and many of the remainder have subclinical seizure-like brain activity. However, little is known about which traditional epilepsy treatments and commonly used non-traditional alternative treatments are effective for treating seizures or epilepsy in children and adults with autism spectrum disorder.

25 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Since 2008, the U.S. economy has been "seizing" uncontrollably. Now a Tel Aviv University researcher says that a comparison of the multifaceted economic downturn with the uncontrolled spasms of an epileptic is not inappropriate - and may say something about the origins of the disaster.

13 May 2011

NAA calls for immediate Congressional hearings and scientific investigation into autism-vaccine link

Despite numerous studies cited repeatedly by federal officials as proof that vaccines do not cause autism, a new study released today in the Pace Environmental Law Review revealed that over the last two decades, the National Vaccine Injury Compensation Program has been quietly compensating dozens of vaccine injury cases involving a child with autism.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Seizure News and Research

Latest Seizure News and Research

Insight into beneficial epilepsy treatments for children with autism

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

FDA warns online retailers for illegal tobacco product marketing

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec launches educational forum, 'Women in MS'

Study provides insight into effective treatments for autism spectrum disorder, seizures

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Researcher says a comparison with epilepsy is an appropriate prism to view economics

NAA calls for immediate Congressional hearings and scientific investigation into autism-vaccine link

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Acorda reports $0.7 million GAAP net loss for first quarter 2011

FTC, FDA take action on unproven STD drug products

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

Cyberonics initiates first implant of AspireSR product in epilepsy patients

Everything you need to know about epilepsy eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Seizure News and Research

Latest Seizure News and Research

Everything you need to know about epilepsy eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in